公开(公告)号：EP2572727B1

公开(公告)日：2016-05-18

申请号：EP12187538.9

申请日：2008-04-23

申请人： Valneva

发明人： Guehenneux, Fabienne ,  Moreau, Karine ,  Esnault, Magali ,  Mehtali, Majid

IPC分类号： A61K39/12 ,  A61K39/17 ,  A61K39/285 ,  C12N5/0735 ,  C12N7/00 ,  A61K39/00 ,  A61K39/145

CPC分类号： C12N7/00 ,  A61K39/00 ,  A61K39/12 ,  A61K39/145 ,  A61K39/17 ,  A61K39/285 ,  A61K2039/525 ,  C12N5/00 ,  C12N5/0606 ,  C12N2501/105 ,  C12N2501/115 ,  C12N2501/125 ,  C12N2501/13 ,  C12N2501/23 ,  C12N2501/2306 ,  C12N2710/24134 ,  C12N2710/24151 ,  C12N2760/16034 ,  C12N2760/16051 ,  C12N2760/18134 ,  C12N2760/18151 ,  C12N2760/18434 ,  C12N2760/18451

公开(公告)号：EP2947149A1

公开(公告)日：2015-11-25

申请号：EP15173487.8

申请日：2008-06-20

申请人： Alphavax, Inc.

发明人： KAMRUD, Kurt I. ,  SMITH, Jonathan F. ,  MAUGHAN, Maureen

IPC分类号： C12N15/63 ,  C12N15/40 ,  C07K14/705 ,  A61K38/00 ,  C12N15/86 ,  A61K39/12 ,  A61K39/00 ,  A61K39/285

CPC分类号： C12N15/86 ,  A61K39/12 ,  A61K39/285 ,  A61K2039/5256 ,  C12N2710/24134 ,  C12N2770/36134 ,  C12N2770/36143

摘要： The present invention provides use of an isolated RNA molecule comprising: a) an alphavirus 5' replication recognition sequence, wherein at least one initiation codon has been removed from the 5' replication recognition sequence; b) a nucleotide sequence encoding an alphavirus structural protein; and c) an alphavirus 3' replication recognition sequence, with the proviso that the RNA molecule does not contain a promoter that directs transcription of the nucleotide sequence of (b), and wherein the alphavirus 5' and 3' replication recognition sequences of (a) and (c) direct replication of the RNA molecule in the presence of alphavirus nonstructural proteins in inducing an immune response in a subject or for use in immunizing a subject or for treating a subject.

摘要翻译： 本发明提供分离的RNA分子的用途，其包括：a）甲病毒5'复制识别序列，其中至少一个起始密码子已经从5'复制识别序列中除去; b）编码甲病毒结构蛋白的核苷酸序列; 和c）甲病毒3'复制识别序列，条件是RNA分子不含有指导（b）的核苷酸序列的转录的启动子，并且其中（a）的甲病毒5'和3'复制识别序列 ）和（c）在甲病毒非结构蛋白存在下RNA受体的直接复制以诱导受试者中的免疫应答或用于免疫受试者或用于治疗受试者。

公开(公告)号：EP2191836B1

公开(公告)日：2012-05-23

申请号：EP08828811.3

申请日：2008-08-28

申请人： Kyushu University, National University Corporation ,  Nippon Zoki Pharmaceutical Co., Ltd.

发明人： OISHI, Ryozo ,  ITOH, Yoshinori ,  EGASHIRA, Nobuaki

IPC分类号： A61K35/36 ,  A61K35/12 ,  A61K39/285 ,  A61P25/02 ,  A61P25/04 ,  A61P43/00

CPC分类号： A61K35/36 ,  A61K35/76 ,  C12N2710/24132 ,  A61K2300/00

摘要： There is provided a medicinal agent that is effective and highly safe for the prevention or alleviation of a peripheral nerve disorder that develops as a side effect occurring after the administration of an anti-cancer agent. The present invention relates to a novel medical use of an extract from inflamed tissues inoculated with vaccinia virus, and to a prophylactic or alleviating agent for a peripheral nerve disorder that contains the extract as an active ingredient. The agent containing the extract as an active ingredient is used for a prophylactic or alleviating agent for a peripheral nerve disorder induced by an anti-cancer agent and is a highly safe and remarkably highly useful medicinal agent with few side effects.

公开(公告)号：EP2363143A3

公开(公告)日：2012-02-15

申请号：EP10012380.1

申请日：2004-03-29

申请人： The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services ,  The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. ,  THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, DEPARTMENT OF THE ARMY

发明人： Moss, Bernard ,  Earl, Patricia L. ,  Wyatt, Linda ,  Eller, Leigh Anne

IPC分类号： A61K39/12 ,  A61K39/275 ,  A61K39/21 ,  A61K39/285

CPC分类号： C12N15/86 ,  A61K2039/5256 ,  A61K2039/53 ,  A61K2039/57 ,  C07K14/005 ,  C12N2710/24143 ,  C12N2740/16122 ,  C12N2740/16222 ,  C12N2830/00 ,  C12N2830/15 ,  C12N2830/60

摘要： The invention provides modified vaccinia Ankara (MVA), a replication-deficient strain of vaccinia virus, expressing human immunodeficiency virus (HIV) env, gag, and pol genes.

公开(公告)号：EP2362782A1

公开(公告)日：2011-09-07

申请号：EP09760327.8

申请日：2009-11-17

申请人： The Provost, Fellows, Foundation Scholars, and the other Members of Board, of the College of the Holy and Undivided Trinity of Queen Elizabeth

发明人： BOWIE, Andrew, Graham ,  HARRINGTON, Barry, Noel ,  LYSAKOVA, Tatyana Sergeevna ,  KEOGH, Brian

IPC分类号： A61K39/285 ,  C07K5/10 ,  C07K7/06 ,  C07K7/08 ,  C07K14/005 ,  C07K14/07

CPC分类号： G01N33/566 ,  A61K38/00 ,  A61K39/00 ,  C07K5/1019 ,  C07K14/005 ,  C12N2710/24122 ,  G01N2333/705 ,  G01N2500/02 ,  G01N2500/10

摘要： A peptide for inhibiting Toll-like receptor 4 (TLR4) signalling comprising the amino acid sequence of SEQ ID NO. 4, SEQ ID NO 55, SEQ ID NO 68, SEQ ID NO. 69, SEQ ID NO 70, SEQ ID NO 71, SEQ ID NO 72, SEQ ID NO 79, SEQ ID NO 82, SEQ ID NO 85, SEQ ID NO 88, SEQ ID NO 91, SEQ ID NO 94, SEQ ID NO 97, SEQ ID NO 100, SEQ ID NO 103, SEQ ID NO 106, SEQ ID NO 109, SEQ ID NO 112, or SEQ ID NO 115. The peptide may comprise a delivery sequence such as a cationic peptide.

公开(公告)号：EP2191836A4

公开(公告)日：2011-03-30

申请号：EP08828811

申请日：2008-08-28

申请人： UNIV KYUSHU NAT UNIV CORP ,  NIPPON ZOKI PHARMACEUTICAL CO

发明人： OISHI RYOZO ,  ITOH YOSHINORI ,  EGASHIRA NOBUAKI

IPC分类号： A61K35/36 ,  A61K35/12 ,  A61K39/285 ,  A61P25/02 ,  A61P25/04 ,  A61P43/00

CPC分类号： A61K35/36 ,  A61K35/76 ,  C12N2710/24132 ,  A61K2300/00

摘要： There is provided a medicinal agent that is effective and highly safe for the prevention or alleviation of a peripheral nerve disorder that develops as a side effect occurring after the administration of an anti-cancer agent. The present invention relates to a novel medical use of an extract from inflamed tissues inoculated with vaccinia virus, and to a prophylactic or alleviating agent for a peripheral nerve disorder that contains the extract as an active ingredient. The agent containing the extract as an active ingredient is used for a prophylactic or alleviating agent for a peripheral nerve disorder induced by an anti-cancer agent and is a highly safe and remarkably highly useful medicinal agent with few side effects.

公开(公告)号：EP2204179A3

公开(公告)日：2010-12-22

申请号：EP10158052.0

申请日：2003-04-16

申请人： Bavarian Nordic A/S

发明人： Chaplin, Paul ,  Suter, Mark ,  Ackermann, Mathias ,  Franchini, Marco ,  Vollstedt, Sabine ,  Hefti, Hans-Peter

IPC分类号： A61K39/285 ,  A61K39/12 ,  A61K39/00 ,  A61K39/02

CPC分类号： A61K39/285 ,  A61K39/12 ,  A61K39/245 ,  A61K2039/5254 ,  A61K2039/55 ,  A61K2039/58 ,  C12N7/00 ,  C12N2710/16634 ,  C12N2710/24134 ,  C12N2710/24143 ,  C12N2710/24151 ,  C12N2710/24161 ,  Y02A50/386 ,  Y02A50/39 ,  Y02A50/394

摘要： The invention concern the use of a virus for the preparation of a medicament for the vaccination or treatment of a neonatal or prenatal animal, including a human, wherein the virus is capable of infecting the cells of the neonatal or prenatal animal, including a human, but not capable of being replicated to infectious progeny virus in the neonatal or prenatal animal, including a human. The virus is preferably a Modified Vaccinia Virus Ankara.
In particular, the invention concerns the vaccination of neonates against infections with viruses belonging the same virus group than the virus used for vaccination. Moreover, the invention concerns the vaccination of neonates against antigens selected from foreign antigens and tumour antigens, wherein the tumour antigen and/or the foreign antigen are different from the antigens associated with the virus. The invention further concerns the use of viruses as defined above to increase the level of factors which activate dendritic cells or their precursor cells and/or to increase the number of dendritic cells or their precursor cells and/or to increase the production and/or cellular content of an interferon (IFN) or IL·12.

公开(公告)号：EP1845164B1

公开(公告)日：2010-06-16

申请号：EP07014231.0

申请日：2004-01-17

申请人： Bavarian Nordic A/S

发明人： Leyrer, Sonja, Dr.

IPC分类号： C12N15/863 ,  A61K39/285

CPC分类号： C07K14/005 ,  A61K39/12 ,  A61K39/285 ,  A61K48/00 ,  A61K2039/5256 ,  C12N15/86 ,  C12N2710/24143

摘要： The invention concerns promoters, in particular for the expression of genes and/or coding sequences in vaccinia viruses such as Modified vaccinia virus Ankara (MVA). The invention further concerns expression cassettes comprising said promoter, vectors comprising said expression cassettes as well as pharmaceutical compositions and vaccines.

公开(公告)号：EP0833923B2

公开(公告)日：2010-03-17

申请号：EP96917380.6

申请日：1996-05-15

申请人： Bio-Products & Bio-Engineering Aktiengesellschaft

发明人： MANNHALTER, Josef, W. ,  LEIBL, Heinz ,  EIBL, Martha

IPC分类号： C12N15/33 ,  C12N15/86 ,  A61K39/21 ,  A61K39/285

CPC分类号： A61K39/12 ,  A61K39/08 ,  A61K2039/5252 ,  A61K2039/55544 ,  A61K2039/6037 ,  A61K2039/70 ,  C12N2770/24034 ,  Y02A50/396

公开(公告)号：EP1372710B1

公开(公告)日：2009-10-14

申请号：EP02721259.6

申请日：2002-03-01

申请人： THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES ,  EMORY UNIVERSITY

发明人： MOSS, Bernard ,  WYATT, Linda ,  EARL, Patricia ,  ROBINSON, Harriet, L.

IPC分类号： A61K39/12 ,  A61K39/21 ,  A61K39/275 ,  A61K39/285

CPC分类号： A61K39/21 ,  A61K39/12 ,  A61K2039/525 ,  A61K2039/53 ,  A61K2039/545 ,  A61K2039/57 ,  A61K2039/70 ,  C07K14/005 ,  C12N15/86 ,  C12N2710/24143 ,  C12N2710/24171 ,  C12N2740/15022 ,  C12N2740/15034 ,  C12N2740/16034 ,  C12N2740/16122 ,  C12N2740/16134 ,  C12N2740/16222 ,  C12N2740/16234 ,  C12N2830/00 ,  C12N2830/15 ,  C12N2830/60

摘要： The invention provides modified virus Ankara (MVA), a replication-deficient strain of vaccinia virus, expressing human immunodeficiency virus (HIV) env, gag, and pol genes.